Study suggests T-cells don t determine survival in severe COVID-19
The coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes mild to moderate illness in the general population. Some people, however, may experience severe symptoms, which can be potentially fatal.
Severe COVID-19 has been tied to T cell lymphopenia, but no causal effect of T cell deficiency on disease severity has been established.
Researchers at the Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health found that T cell-depleted groups of rhesus macaques developed virus-neutralizing antibody responses and also class-switched to immunoglobulin G (IgG).
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
AB Science announces the signing of an exclusive licensing agreement with the University of .
AB ScienceApril 6, 2021 GMT
PRESS RELEASE
AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS
Paris, April 6 2021, 8am CET
AB Science SA (Euronext - FR0010557264 - AB), together with the University of Chicago, to
Is non-severe SARS-CoV-2 infection characterized by early T cell proliferation?
The extent of severity of the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), varies from asymptomatic, mild to severe. Scientists found that during the first wave of the pandemic, individuals infected with non-severe SARS-CoV-2, before the onset of the vaccination program, induced effective host-defense mechanisms in naive populations.
To date, little evidence has been documented regarding the immune responses after the onset of the symptoms or virus detection. Further, no cross-sectional studies have been conducted that define the time of infection. Thereby, no report is available that explains the relationship between the earliest immune responses to COVID-19 and temporal kinetics. Scientists believe that understanding the early immune response regarding the asymptomatic or mildly infected population may help determine the factors associate
Researchers identify a novel SARS-CoV-2 variant (A.VOI.V2) in southern Africa
A team of international scientists has recently explored the transmission dynamics of currently circulating variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a southern African country. By analyzing the genomic sequences of these variants, they have identified a novel SARS-CoV-2 variant with multiple spike mutations. They have temporarily designated the variant A.VOI.V2. A detailed description of the genomic surveillance they carried out is currently available on the
Background
Since its emergence in December 2019, SARS-CoV-2, the causative pathogen of coronavirus disease 2019 (COVID-19), has undergone more than 12,000 mutations. The majority of these mutations are found in the viral spike protein, which is a glycoprotein on the viral envelope required for establishing SARS-CoV-2 infection. Because of robust immunogenicity, the spike protein is considered to be the most potent
New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks
In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift generation of antibodies and the potential to protect individuals who cannot receive other COVID-19 vaccines for medical reasons. The research is posted to the
bioRxiv preprint server.
Vaccines currently in use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a causative agent of COVID-19, focus on the viral spike glycoprotein that mediates cell entry by targeting angiotensin receptor 2 (ACE2) as the main receptor and heparin as the co-receptor.